BACKGROUNDUrinary bladder cancer is the 9 th most common cancer worldwide and 13 th most numerous cause of death from cancer. VEGF expression has been shown to be a prognostic marker and predicts the risk of recurrence and its high expression is related to lymph node metastasis. The study was undertaken to determine the expression of VEGF in urinary bladder tumours and its possible benefits in determining the prognosis of patients. MATERIALS AND METHODS50 cases of transitional cell carcinoma of urinary bladder diagnosed by histopathology were taken and expression of VEGF was observed on immunohistochemistry the results of staining intensity and percentage of positive cells were added and final scoring was done. RESULTSExpression of VEGF correlated with grade of tumor and was found to be statistically significant (p<0.05). Maximum number of patients with high grade TCC showed a score of 3 for VEGF whereas in maximum patients with low grade TCC score of 1 for VEGF was obtained. CONCLUSIONExpression of VEGF was found to be higher in patients with high grade TCC as compared to low grade TCC. Therefore, VEGF can be used as an important IHC marker to assess the utilization of antiangiogenic therapy in patients with urinary bladder malignancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.